Publications by authors named "M Brizzi"
Background: Opioids are effective for post-operative pain control but are no longer considered appropriate as the sole method for managing pain after surgery. Newer, multimodal approaches to pain control are increasingly being employed to decrease reliance on opioids, but patient-related outcomes are not consistently reported with these interventions.
Objective: This study evaluated the effect of implementing a new multimodal therapy order set, coupled with new patient education materials, on post-operative outcomes after complex shoulder surgery.
Article Synopsis
- Antiretroviral drug resistance is a growing global issue that threatens efforts to end the HIV epidemic, particularly with rising rates of integrase resistance.
- Heavily treatment-experienced individuals living with HIV face limited treatment options and a higher risk of serious health issues, necessitating better management strategies.
- This review aims to explore effective identification and management of these individuals, focusing on innovative resistance mechanisms and treatment approaches in both resource-rich and resource-limited environments.
Background: The first long-acting injectable antiretroviral, cabotegravir/rilpivirine (LA-CAB/RPV), was FDA approved in January 2021 for persons with HIV suppressed on their current regimen. Body mass index (BMI) ≥30 kg/m2 has been identified as a risk factor for virologic failure, however data is limited due to small sample sizes. The aim of this study was to evaluate the impact of BMI on the efficacy of LA-CAB/RPV in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- A case study of a 52-year-old man showed he developed right ocular myositis and dacryocystitis, treated successfully with intravenous acyclovir and oral steroids; literature review of 29 patients shows a median age of 61 and a female predominance.
- Effective treatment typically involves intravenous antiviral therapy within 72 hours and may include systemic corticosteroids, with a full resolution of symptoms achieved in about 51.7% of patients.
A cutting-edge approach in cell-based immunotherapy for combating resistant cancer involves genetically engineered chimeric antigen receptor T (CAR-T) lymphocytes. In recent years, these therapies have demonstrated effectiveness, leading to their commercialization and clinical application against certain types of cancer. However, CAR-T therapy faces limitations, such as the immunosuppressive tumour microenvironment (TME) that can render CAR-T cells ineffective, and the adverse side effects of the therapy, including cytokine release syndrome (CRS).
View Article and Find Full Text PDF